Clinical Trial Detail

NCT ID NCT03285412
Title CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer
Recruitment Recruiting
Gender female
Phase
Variant Requirements yes
Sponsors
Indications

Her2-receptor negative breast cancer

Therapies

Ribociclib

Age Groups: adult senior

Additional content available in CKB BOOST